Aigen Investment Management LP Invests $213,000 in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Aigen Investment Management LP purchased a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 25,591 shares of the company’s stock, valued at approximately $213,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in AMRX. Vanguard Group Inc. lifted its position in shares of Amneal Pharmaceuticals by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company’s stock valued at $83,193,000 after acquiring an additional 85,846 shares during the period. Rubric Capital Management LP raised its holdings in Amneal Pharmaceuticals by 12.4% during the second quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock worth $68,083,000 after purchasing an additional 1,179,830 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Amneal Pharmaceuticals by 17.6% during the second quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock worth $27,205,000 after purchasing an additional 641,405 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in Amneal Pharmaceuticals by 1.9% in the second quarter. Nantahala Capital Management LLC now owns 2,669,943 shares of the company’s stock valued at $16,954,000 after purchasing an additional 50,000 shares during the last quarter. Finally, BlackBarn Capital Partners LP increased its position in shares of Amneal Pharmaceuticals by 41.5% in the second quarter. BlackBarn Capital Partners LP now owns 2,000,000 shares of the company’s stock valued at $12,700,000 after buying an additional 586,703 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Down 5.9 %

AMRX stock opened at $8.47 on Friday. The stock has a market capitalization of $2.62 billion, a price-to-earnings ratio of -12.46 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a 52-week low of $4.16 and a 52-week high of $9.48. The stock’s fifty day simple moving average is $8.58 and its 200-day simple moving average is $7.65.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. StockNews.com raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 11th. Truist Financial increased their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, October 2nd. Barclays lifted their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price on the stock in a report on Friday, September 6th. Finally, Piper Sandler boosted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $10.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.